← FDA DRUG APPROVALS

FDA ANDA · ANDA201950

RASAGILINE MESYLATE

Sponsor: APOTEX INC

APPLICATION
ANDA201950
TYPE
ANDA
ORIGINAL APPROVAL
2013-09-12
LATEST ACTION
2015-12-17
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

RASAGILINE MESYLATEDiscontinued
RASAGILINE MESYLATE EQ 0.5MG BASE · TABLET · ORAL
RASAGILINE MESYLATEDiscontinued
RASAGILINE MESYLATE EQ 1MG BASE · TABLET · ORAL

Approval history

2015-12-17Labeling · Supplement 1 · standardAP
2013-09-12Not Applicable · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →